Global Biological Therapies for Cancer Market 2022-2028

September 2022 | 80 pages | ID: G7271DDF2961EN
Gen Consulting Company

Abstracts

The global biological therapies for cancer market is expected to increase by USD 50 billion, at a compound annual growth rate (CAGR) of 8.2% from 2022 to 2028, according to the latest edition of the Global Biological Therapies for Cancer Market Report.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global biological therapies for cancer market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the biological therapies for cancer industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, and region. The global market for biological therapies for cancer can be segmented by product: CAR T-cell therapies, monoclonal antibodies, vaccines. The monoclonal antibodies segment held the largest share of the global biological therapies for cancer market in 2021 and is anticipated to hold its share during the forecast period. Biological therapies for cancer market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW). Globally, North America made up the largest share of the biological therapies for cancer market.

By product:

• CAR T-cell therapies
• monoclonal antibodies
• vaccines

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The report also provides a detailed analysis of several leading biological therapies for cancer market vendors that include Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Janssen Pharmaceuticals, Inc., Merck KGaA, Novartis International AG, Pfizer Inc., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global biological therapies for cancer market.
• To classify and forecast the global biological therapies for cancer market based on product, region.
• To identify drivers and challenges for the global biological therapies for cancer market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biological therapies for cancer market.
• To identify and analyze the profile of leading players operating in the global biological therapies for cancer market.

Why Choose This Report

• Gain a reliable outlook of the global biological therapies for cancer market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY PRODUCT

CAR T-cell therapies
Monoclonal antibodies
Vaccines

PART 6. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 7. KEY COMPANIES

Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche AG
Genmab A/S
Gilead Sciences, Inc.
GlaxoSmithKline plc (GSK)
Janssen Pharmaceuticals, Inc.
Merck KGaA
Novartis International AG
Pfizer Inc.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER